Nucleic AcidHub 2025
The 4th China Nucleic Acid Drug and Neotype Vaccine Industrial Conference
BIA 2025
Asia Beauty Injection Medical Aesthetics Summit

Nucleic AcidHub 2024-The 3rd China Nucleic Acid Drug and Neotype Vaccine Industrial Conference, organized by Taas Labs, will be held on May 8th-9th, 2024 in Shanghai, China. The award ceremony of "The 2nd China Nucleic Acid Drugs and Neotype Vaccines Star of the Year Award" will be held at the same time. Focusing on Global RNA Technology Trend Overview, Innovation in MicroRNA Development, Vaccine Development and Progress(mRNA vaccines and therapeutic, prophylactic, peptide cancer vaccines), Innovation Studies and Cutting Edge Technologies, Peptide Drug Development, RNA Drug CMC Development and Manufacturing Processes and Deliver Platform, there will be 50+ industry experts to share their insights and application cases on-site, 50+ exhibitors to showcase the latest technologies and solutions, 1000+ domestic and foreign participants to attend the event, gathering guests from top nucleic acid vaccine companies and relevant personnel from the upstream and downstream industry chain, striving to promote the scientific and technological innovation and industrial integration and development of nucleic acid vaccines. Welcome to attend Nucleic AcidHub 2024-the 3rd China Nucleic Acid Drug and Neotype Vaccine Industrial Conference!

• Focusing on Chronic Disease & Keeping Sustainable Innovation Based on Clinical Needs
  

• Case Sharing: Chinese siRNA Drug Development - Success and Failure
  

• AI-Driven Nucleic Acid Drug Delivery and Drug Discovery
  

• Case Study: ASO Drug Development for Duchenne Muscular Dystrophy
  

• Effect of mRNA Sequence Design on Synthesis and Capping Processes
  

• Small Nucleic Acid for Hepatitis B, Innovative siRNA Therapeutics Development and Registration Experience Sharing
  

• Non-Hepatic Targeted Delivery System--AOC, A Micro Nucleic Acid Coupled Substance
  

• Advances in Inhaled Nucleic Acid Delivery and Extrahepatic Targeted Delivery
  

• Advances in Peptide and Dual-Target Coupled Drugs (Bi-XDC) and Prospects for Drug Success
  

• Cancer Vaccine Clinical Development Strategy

• ......